Daiad-2/15 / StradBio - LARVOL DELTA

Daiad-2/15: A conditionally active, targeted, hyperpotent IL-2/IL-15 immune agonist is safe and effective in vivo (AACR 2026) - "Together, our data suggest that Daiad-2/15 could potentiate the systemic delivery of a highly potent immune agonist to specific immune cells in the tumor microenvironment and draining lymph nodes with a wide therapeutic index. Additional preclinical studies are underway, and clinical testing of Daiad-2/15 is planned."

Preclinical • Oncology • IL15 • IL2 • LAG3 • PD-1

Conditional Immune Activation with Daiad-2/15: a Targeted, Hyperpotent IL-2/IL-15 Agonist with an Engineered Logic Gate (SITC 2025) - "Furthermore, Daiad-2/15 does not trans-activate target-negative cells, even when present in an admixed culture. Finally, Daiad technology enables an 'and' logic gate by targeting each of the inactive domains to different targets, such that immune cell activation and proliferation only occur when both targets are present on the same cell.Conclusions Together, our data suggest that Daiad-2/15 could potentiate the systemic delivery of a highly potent immune agonist to specific immune cells within the tumor microenvironment and draining lymph nodes in the absence of significant systemic toxicity."

Oncology • IL15 • IL2 • IL2RA